SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q3 Trading Update

18 Oct 2018 07:00

RNS Number : 4043E
Rentokil Initial PLC
18 October 2018
Β 

RENTOKIL INITIAL PLC (RTO) - THIRD QUARTER TRADING UPDATE

18 October 2018

Β 

Β 

(Β£m)

Q3 2018

Growth

AER

AER

CER

Ongoing Revenue1

637.4

10.2%

11.8%

Revenue

641.1

6.3%

8.2%

Β 

Overview (CER)

Β 

Ongoing Revenue increased by 11.8% in Q3, of which 4.1% was Organic Revenue2 growth (H1 2018: 3.0%, Q3 2017: 3.7%) and 7.7% was from acquisitions. Adjusting for the impact of Hurricane Irma on our operations in Puerto Rico in September 2017, Group Organic growth was 4.4%.

Pest Control grew by 11.4% (5.3% Organic and 5.7% adjusting for Puerto Rico), with good performances being delivered across both Growth and Emerging markets. The business enjoyed favourable weather conditions across Europe and the UK which has supported stronger jobbing revenues. North America grew Ongoing Revenue by 12.1% (4.6% Organic and 5.3% adjusting for Puerto Rico).

Hygiene revenues increased by 22.0% (2.8% Organic) reflecting continued progress from initiatives to drive Organic growth and the contribution from the acquisitions of Cannon Hygiene Services and CWS Italy. Ongoing Revenue in our Protect & Enhance markets grew by 0.7% (0.7% Organic) reflecting improvements in France Workwear and Ambius. Ongoing market weakness continued to impact the performance of our UK Property Care business in the third quarter, albeit this was at an improved rate of decline compared to H1.Β 

M&A

​We acquired 16 businesses (14 in Pest Control, one in Hygiene and one in Ambius) across all our regions in Q3 with annualised revenues of Β£39.0m. For the year to 30 September 2018 we have acquired a total of 39 businesses (34 in Pest Control, four in Hygiene and one in Ambius) primarily in Emerging and Growth markets. Annualised revenues of the businesses acquired so far in 2018 totalled Β£156.3m in the year prior to purchase. Our M&A pipeline going into Q4 and 2019 remains strong.

​Commenting on today's announcement Andy Ransom, Chief Executive, said:

"I am pleased with the performance of the group in the third quarter. We continue to successfully deploy our market-leading innovations and digital applications to our customers and to execute our value-creating M&A programme, and we remain on track to meet expectations for the full year."

Β 

Enquiries:

Β 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

Β 

Β 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

Β 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

Β 

AER - actual exchange rates; CER - constant 2016 exchange rates

Β 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
TSTZMMMGNNMGRZM
Date   Source Headline
21st May 20267:00 amRNSAppointment of CEO, North America
8th May 202610:30 amRNSHolding(s) in Company
7th May 20264:40 pmRNSResult of AGM
23rd Apr 20264:25 pmRNSFinal Dividend – Pence Sterling Amount Payable
23rd Apr 20262:30 pmRNSIssuance of $500 million 4.625% Notes due 2031
21st Apr 202610:30 amRNSHolding(s) in Company
16th Apr 20267:00 amRNSQ1 Trading Update
15th Apr 20267:00 amRNSDirectorate Change
30th Mar 202610:30 amRNSHolding(s) in Company
26th Mar 20263:46 pmRNSDirector/PDMR Shareholding
25th Mar 202610:50 amRNSAnnual Financial Report
17th Mar 20264:30 pmRNSDirector/PDMR Shareholding
16th Mar 202610:32 amRNSHolding(s) in Company
16th Mar 202610:32 amRNSHolding(s) in Company
12th Mar 202610:30 amRNSHolding(s) in Company
10th Mar 20264:28 pmRNSDirector/PDMR Shareholding
10th Mar 20264:28 pmRNSDirector/PDMR Shareholding
10th Mar 20264:26 pmRNSDirector/PDMR Shareholding
10th Mar 20264:26 pmRNSDirector/PDMR Shareholding
9th Mar 202611:15 amRNSHolding(s) in Company
5th Mar 20267:00 amRNSPreliminary Results
5th Mar 20267:00 amRNSChair Succession Planning Update
23rd Feb 202610:30 amRNSHolding(s) in Company
19th Feb 20262:50 pmRNSDirector Declaration
12th Feb 20265:30 pmRNSNotice of Early Redemption
20th Jan 202610:25 amRNSHolding(s) in Company
19th Jan 202610:30 amRNSHolding(s) in Company
16th Jan 20263:00 pmRNSHolding(s) in Company
14th Jan 202610:30 amRNSHolding(s) in Company
13th Jan 202610:30 amRNSHolding(s) in Company
13th Jan 20267:00 amRNSDirectorate change
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
5th Dec 202510:30 amRNSHolding(s) in Company
5th Dec 202510:30 amRNSHolding(s) in Company
26th Nov 20254:25 pmRNSHolding(s) in Company
28th Oct 202510:45 amRNSHolding(s) in Company
28th Oct 202510:45 amRNSHolding(s) in Company
27th Oct 202510:30 amRNSHolding(s) in Company
23rd Oct 202511:45 amRNSHolding(s) in Company
23rd Oct 20257:00 amRNSQ3 Trading Update
21st Oct 202510:00 amRNSHolding(s) in Company
14th Oct 202510:00 amRNSHolding(s) in Company
1st Oct 202510:30 amRNSBlock listing Interim Review
30th Sep 202510:30 amRNSCompletion of France Workwear business sale
25th Sep 20254:15 pmRNSDirector/PDMR Shareholding
24th Sep 20256:00 pmRNSDirector Declaration
26th Aug 202512:30 pmRNSInterim Dividend – Pence Sterling Amount Payable
7th Aug 202511:10 amRNSHolding(s) in Company
31st Jul 20257:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.